

Orgenesis, Atvio to present at the WATRM Congress

17 May 2018 | News

Featured on Two Panels Highlighting New Development Processes, Automation Tools and Logistics Services Designed to Accelerate Cell Therapy Development, Reduce Costs, and Streamline the Delivery of Therapeutics.

WORLD
**ADVANCED THERAPIES &
REGENERATIVE MEDICINE**
CONGRESS 2018

Orgenesis Inc., a manufacturer, service provider and developer of advanced cell therapies has announced that the Company, along with its CDMO partner, Atvio Biotechnology (Atvio) based in Israel, will be featured on two panels at the World Advanced Therapies & Regenerative Medicine Congress being held May 16 - 18 in London. The World Advanced Therapies and Regenerative Medicine Congress includes both a world-class conference where business leaders from around the world meet and a unique exhibition for pharmaceutical, biotech and research experts.

Dr. Ohad Karnieli, Ph.D., MBA, Chief Executive Officer of Atvio will speak on the panel, "Regulation, Pricing, Reimbursement & Market Access of Advanced Therapies Around the Globe" as part of the conference's C-Level Forum. He will also speak on the "Assessment of Health Technology and Market Access Globally, Challenges and Pricing" panel that will explore logistical challenges for cell and gene therapies in the future and will discuss how innovation plays a large role in market access.

Dr. Karnieli plans to discuss how Orgenesis's subsidiary, MaSTherCell, and Atvio have evolved their business model well beyond a traditional contract development and manufacturing organization (CDMO) by focusing on improving their clients' therapeutic development processes, providing low-cost and decentralized manufacturing, logistical services and complete life-cycle management.

Dr. Efrat Assa Kunik, General Manager of Orgenesis Ltd, the company's Israeli subsidiary developing its diabetic therapy, commented, "We look forward to participating in this distinguished conference and having our technologies featured alongside Atvio on two panels at the World Advanced Therapies & Regenerative Medicine Congress. Importantly, we plan to discuss how innovation is at the core of our diabetic development program with our use of Insulin Producing Cells (IPCs). We are jointly creating unique development processes and automation tools designed to accelerate cell therapy development, reduce costs, and streamline the delivery of therapeutics to patients through a decentralized manufacturing and services model."

Dr. Karnieli also presented Orgenesis's and Atvio's new model in a keynote panel presentation at the International Society for Cell & Gene Therapy (ISCT) 2018 Annual Meeting held May 2 - 5, 2018 in Montreal, Canada.